This trial is evaluating whether Learn to Quit App will improve 1 primary outcome, 7 secondary outcomes, and 8 other outcomes in patients with Manic Disorder. Measurement will happen over the course of Weeks 0-24.
This trial requires 450 total participants across 1 different treatment group
This trial involves a single treatment. Learn To Quit App is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"People with schizoaffective disorders accounted for 3.2% of the whole US population sampled and comprised 1% of those with a prior diagnosis of any mood or anxiety disorder." - Anonymous Online Contributor
"It is not known what predisposes to development of schizoaffective disorders. If we knew this, it might contribute toward providing new treatments and better understanding of schizoaffective disorder." - Anonymous Online Contributor
"Schizoaffective disorder is a psychiatric disorder that involves experiences of mood swings between mania and depression that is often characterized by mood symptoms that resemble a mood disorder. It is distinguished from bipolar disorder by the absence of manic episodes.\n" - Anonymous Online Contributor
"At the time of the study, no consensus existed regarding optimal treatment for SPD. This review summarizes the treatments currently used to treat SPD, and provides a rating of the treatments' evidence base." - Anonymous Online Contributor
"Schizoaffective disorders have a very high risk of recurrence. Patients treated with cognitive behavioral therapy are at statistically significantly lower risk to relapse than patients treated with antidepressant agents alone, irrespective of the type of antidepressant medication (tricyclic or fluoxetine. However, these results will have to be confirmed in a randomized controlled trial." - Anonymous Online Contributor
"Schizoaffective disorders can have a variety of physical signs and symptoms. Many of these symptoms appear with acute mania and may disappear with hypomania, however the most common physical signs are swelling of the face or an abnormal lump on the back of your neck. Treatment of schizoaffective disorder can be complicated, and may require hospitalisation or admission. There are many other types of bipolar disorders, the symptoms and treatment of which are not discussed here.\n" - Anonymous Online Contributor
"As of August 31, 2013, no clinical trial of either V-CAT or Learn to Quit has been accepted for publication (see http://clinicaltrials.gov/ct2/show/NCT00262736) reflecting the preliminary findings of a recent clinical study." - Anonymous Online Contributor
"This app's primary aim is to provide evidence-based support for quitting smoking by informing people and helping them to control their use of smoking. However, in its use in the clinic, the app showed potential to support other treatment and recovery goals, such as the following:\n- fostering positive and productive interactions between clinicians and patients\n- empowering clients to be more actively involved in their health by sharing coping skills and relapse prevention strategies with other patients\n- reinforcing client autonomy by reducing the sense of being coerced by the clinician\n- enabling clients to work toward their individual treatment objectives as part of a comprehensive recovery program." - Anonymous Online Contributor
"This small study shows the potential for learning to quit to not only improve adherence to anticholinergic medication but to also improve quality of life. Further research is needed to clarify this relationship. Clinicians should routinely work with patients with psychosis to teach skills to quit." - Anonymous Online Contributor
"The presence of psychotic symptoms and a history of depressive episodes are the strongest predictors of suicide in patients with schizophrenia. The presence of symptoms suggestive for psychotic disorder, such as hallucinations or delusions, is a strong predictor of suicidal behavior and death." - Anonymous Online Contributor
"Results from a recent clinical trial found that learning to quit app may not be a valid option for treatment of current smokers in clinical practice. In this sample, those who learned to quit app reported less improvement in symptoms and less satisfaction than did those who did not learn to quit app. Asking about learning to quit app is a valid question in the clinical setting, but this approach should not be used as an adjunct to formal treatments for smoking cessation alone." - Anonymous Online Contributor
"Schizoaffective disorder is a disabling illness that poses special challenges for family, peers, and society. Although it is likely that no single explanatory model, such as biopsychosocial, will be adequate to describe a spectrum of clinical and biological variation among individuals with schizoaffective disorders, our findings from research to date reinforce the relevance of using the DSM-IV categorical approach." - Anonymous Online Contributor